September 10, 2022

damaged tissue in brain And the regeneration of the spinal cord, patients, doctors, families and scientists have been dreaming of this since Multiple sclerosis be. So far no grass has grown for it. While in the relapse stage, many already illness At least in part, very successful brakes are available, and there for progress, from the gradual degeneration PPMS and SPMS courses labeled to date are moderately effective methods (see also MS treatment). in advanced millisecond Standing up to this day Symptomatic treatment spotlight renovation o remyelination It might mean that the damage already done can be repaired, at least in part.

There have been and still are many effective approaches in the mouse model; Only a few of them were able to get approved for progressive MS courses and with rather poor efficiency (see also AMSEL news section)Progressive/progressive MSEven in the current state, it would be irresponsible to raise too much hope.

The objective of the research is to improve the quality of life in cases of advanced MS

In Medryson’s case, the successes so far relate only to a mouse model of MS. However, it should be noted that once once more it shows that researchers around the world are working hard to find better treatments for MS. And: The more new approaches are discovered, the greater the chance that some of them will lead to effective treatments and improve the quality of life for people with advanced MS.

About the study: A research team led by Professor Patrick Currie in Dusseldorf was able to use a mouse model to show that Medryson’s corticosteroid helps replace lost cells and can also restore myelin sheaths. If these findings can be transferred to MS patients, it will be possible to better help those with advanced MS and perhaps, even a bold dream in MS treatment, partially restore lost functions.

the mouse is not human

At this point, it must be emphasized that mice are not human and that rat MS has limited similarities to human MS. In addition, Medryson must be shown to be safe at the required dose, the benefits and risks of side effects must be acceptable, and all of this must be demonstrated in large studies.

Advantage: If you meet these requirements, it may be a bit faster than a completely new active ingredient. Cause: Medryson is an already approved drug in the form of eye drops. It belongs to the corticosteroids and is approved for the treatment of inflammatory eye diseases and eye allergic reactions. As for its neurological effects, it has not yet been investigated. The drug is currently not available in Germany.

The research team led by Professor Patrick Currie has been investigating degenerative and regenerative processes in the central nervous system for many years, also with the aim of finding active ingredients that promote the regeneration process in the brain and spinal cord. In their study, the Dusseldorf team was able to show that astrocytes react specifically to myelin damage. Subtypes appear that partially promote regeneration and partially promote the process of destruction. These processes are very complex.

Unexpected Medryson Effect on Astrocyte Subtypes

Unexpectedly for researchers at a clinic for Neurology from the University Hospital of Düsseldorf that Medrison (given as an injection) in a mouse model promotes the astrocyte subtypes responsible for tissue protection and remyelination and suppresses those that would cause more damage. “This study also indicates that this drug may be of value as a potential treatment for late-stage MS, in which regeneration processes increasingly fail,” the researchers conclude from their findings, while qualifying the need for do more research here. Background in which mice and humans show differences in the interaction of cells of the central nervous system.